Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India. BD The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences...
Posted to
The Medical Quack .... by Barbara Duck
on 11-25-2008
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, clinical trials, R and D, India, Economics, Outsourcing, Employment, Clinic
The general public as a whole are lost when it comes to the complete understanding of how a clinical trial can benefit their potential treatment plans. There is enough information on the web by all means, but how do you get the information to an individual and explain both the potential benefits...
Posted to
The Medical Quack .... by Barbara Duck
on 11-07-2008
Filed under: Medically Related, Technology, drugs, healthcare, EHR, Pharma, PHR, clinical trials, Software integration, Point of Care, Personalized Clinical Trials
The National Cancer Institute has made clinical trial participation a top national priority and yet participant levels are still not perhaps where they could be. Yes, this is a big decision for any patient/physician to make as far as whether or not to enroll, but many trials are offering lifesaving...
Posted to
The Medical Quack .... by Barbara Duck
on 11-02-2008
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Investors, health insurance, Pharma, Cancer, clinical trials, HMO, Pharmaceuticals, R and D, Drug Development, Cancer Institute
Other Pharma businesses have done or will be doing the same, much of R and D is moving other areas where the cost is 1/5 of that here in the US, so 5 times the number of projects ongoing for the same amount of money, which also means in the same terms there can be 4 failures of drugs in the same cost...
Not just India, but other countries as well. I have posted many articles on the blog referencing outsourcing over the last year or so and all of Big Pharma has interests in foreign countries including the strong possibility of phase 1 clinical trials. The one comment I have to make here...
This is probably a good move to speed this process up since many pharmaceutical companies have and are looking at moving more trials to India. More information can be read here about the changing face of Pharma in reference to research and development. One more area to think about too is the use...
Posted to
The Medical Quack .... by Barbara Duck
on 09-19-2008
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Cancer, clinical trials, Congress, DNA Testing, National Cancer Institute, Justice Department
I am guessing this stands to be topic for all in the Pharma business to keep an eye on. There are those in the Indian government too with reservations. The whole idea here is to save money over what the same might cost in the US, as reported earlier, 1/5 is the cost for R and D, thus this...